Annexon, Inc.
ANNX$477M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBRISBANE99 employees
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
ANNX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Vonaprument
Geographic Atrophy
Tanruprubart
Guillain-Barre Syndrome
ANX005
Warm Autoimmune Hemolytic Anemia (wAIHA)
ANX007
Geographic Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vonaprument | Phase 3 | Geographic Atrophy | - | - |
Tanruprubart | Phase 3 | Guillain-Barre Syndrome | - | - |
ANX005 | Phase 3 | Warm Autoimmune Hemolytic Anemia (wAIHA) | - | - |
ANX007 | Phase 2 | Geographic Atrophy | - | - |
Geographic Atrophy
2 drugs in this indication
Guillain-Barre Syndrome
1 drug in this indication
Warm Autoimmune Hemolytic Anemia (wAIHA)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply